Abstract: The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.

Abstract: An object of the invention is to provide a method for producing a capsule or microbead having high encapsulation efficiency of an encapsulated substance, high production efficiency, and high versatility. The invention relates to a method for producing a microcapsule or microbead, comprising: a step of disposing a monomer droplet or polymer droplet containing a substance to be encapsulated, which has a surface coated with a plurality of solid fine particles, on a flat surface; and a step of solidifying the monomer droplet or polymer droplet disposed on the flat surface in a gas phase so as to form an outer shell of a capsule or microbead, thereby forming a region enclosed by the outer shell, wherein the substance is encapsulated in the region.

Abstract: [Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.

Abstract: The present invention provides an inhibitor of an autoimmune response to a periodontal bacterial enzymatic degradation product of keratin in gingival epithelium in a mammal having a periodontal bacterium in the oral cavity, containing a substance having affinity to the keratin or a degradation product thereof and/or a substance having affinity to an autoantibody to the degradation product, an agent for the prophylaxis and/or treatment of a periodontal disease and/or a complication thereof; a RANKL expression inhibitor containing a substance having affinity to the keratin or a degradation product thereof; and a method of diagnosing a periodontal disease including detecting the keratin or a degradation product thereof and/or an autoantibody thereto.

Abstract: According to this invention, the following are provided: a pharmaceutical composition for treating and/or preventing esophageal stenosis, comprising an HGF protein as an active ingredient (wherein the HGF protein may be a polypeptide that is any one of the following: (a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; (b) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2 in which one to several amino acids are deleted, substituted, or added; or (c) a polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 2; and a stent comprising the pharmaceutical composition.

Abstract: The present invention pertains to an antiviral drug for severe fever with thrombocytopenia syndrome, which contains a compound represented by formula (I) or a salt thereof, or a solvate of the compound or salt (In the formula, R1 and R2 are the same or different from each other, and each represents a substituted or unsubstituted C1-10 alkyl group, R1 and R2 may form a substituted or unsubstituted 5- or 6-member ring in conjunction with an adjacent nitrogen atom, and X represent a halogen atom.

Abstract: In a vibration damping device 20, the moment of inertia J1 of a driven member 15, the moment of inertia J2 of an inertial mass body 23, the mass m of crank members 22, the distance L3 between the center of gravity G of the crank member 22 and the fulcrum of swinging of the crank member 22 with respect to the inertial mass body 23, and the distance L4 between this fulcrum and the center of rotation RC are determined so that torque fluctuation of an object for which vibration is to be damped, which is derived based on angular displacement and angles obtained by solving an equation of motion for the driven member 15 and an equation of motion for the entire vibration damping device 20 is equal to a target value.

Abstract: The present invention provides an IgG-binding peptide which can be used for the purification of IgG and has excellent stability, e.g., alkali stability. The present invention also provides a method for purifying IgG using the IgG-binding peptide. Specifically, the present invention relates to a solid-phase support including an IgG-binding peptide, an IgG separation column including the solid-phase support, a kit including the solid-phase support or the column, and a method for purifying IgG using the solid-phase support or the column.

Abstract: The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.

Abstract: In a vibration damping device 20, the moment of inertia J1 of a driven member 15, the moment of inertia J2 of an inertial mass body 23, the mass m of crank members 22, the distance L3 between the center of gravity G of the crank member 22 and the fulcrum of swinging of the crank member 22 with respect to the inertial mass body 23, and the distance L4 between this fulcrum and the center of rotation RC are determined so that torque fluctuation of an object for which vibration is to be damped, which is derived based on angular displacement and angles obtained by solving an equation of motion for the driven member 15 and an equation of motion for the entire vibration damping device 20 is equal to a target value.

Abstract: A novel therapeutic agent and novel anti-HTLV-1 drug for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is provided. A substance capable of inhibiting tyrosine kinase encoded by the ABL1 gene is contained as an active ingredient.

Abstract: A peptide or a salt thereof having an amino acid sequence represented by (a) or (b) shown below having a promotive effect on a proliferation of fibroblast cells, a composition for enhancing proliferation of fibroblast cells containing one or more of them, a composition for enhancing elastin production in fibroblast cells containing one or more peptides or salts thereof having an amino acid sequence represented by (a), (b) or (c) shown below and a composition for enhancing elastin production in chondrocytes containing one or more peptides or salts thereof having an amino acid sequence represented by (c) shown below.

Abstract: AD conversion is performed by using a combination of a parallel AD converter that includes a plurality of comparators to compare an input potential of an analog input signal sampled by a track and hold circuit and reference potentials different from one another and determines a value of a predetermined number of bits on the higher-order side of a digital signal and a single-slope AD converter that reduces the input potential of the analog input signal sampled by the track and hold circuit at a constant speed, converts a time taken until the reduced input potential becomes equal to a reference potential corresponding to the value determined by the parallel AD converter to a digital value, and determines a remaining value on the lower-order side of the digital signal, and thereby the number of bits of the single-slope AD converter can be reduced and high-speed AD conversion is enabled with a small area and low power consumption.

Abstract: This invention relates to an IgG-binding peptide, an IgG-binding peptide modified with a cross-linking agent, a conjugate of the IgG-binding peptide modified with a cross-linking agent and IgG, and a method for producing the conjugate, etc.

Abstract: It is an object of the present invention to provide a novel therapeutic agent for hepatoma viruses. Specifically, the present invention relates to an anti-hepatoma virus agent, containing as an active ingredient a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 is fluorine or hydrogen).

Abstract: A noninvasive method for early detection of a precancerous lesion that may be developed into oral cancer by large-scale screening is provided. The method is a method for obtaining data for diagnosis of an oral precancerous lesion in a subject by detecting methylation of DNA in gargled fluid collected from the subject, wherein the DNA is DNA in a promoter region of at least one gene selected from the following group of genes: RASSF1, DAPK1, CD44, BRCA2, FHIT, CDKN2A, HIC1, CASP8, RAR?, CDKN2B, CHFR, ATM, CDKN1B, BRCA1, and CADM1.

Abstract: [Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.

Abstract: The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

Abstract: A vibration damping device 20 includes: a crank member 22 that is coupled to a driven member 15 via a first coupling shaft A1 and that is swingable about the first coupling shaft A1 along with rotation of the driven member 15; and an inertial mass body 24 that is coupled to the driven member 15 via the crank member 22 and a connecting rod 23 and that is swung about a center of rotation RC in conjunction with the crank member 22 along with rotation of the driven member 15. A component force of a centrifugal force that acts on the crank member 22 along with rotation of the driven member 15 in a direction that is orthogonal to the direction from the center of the first coupling shaft A1 toward the center of gravity G always acts on the crank member 22 as a restoring force that acts to return the inertial mass body 24 to the center of the swing range. The component force is maximum when the inertial mass body 24 is positioned at the center of the swing range.